Asian Patients Report Higher Reflux Symptom Burden than US Patients Despite Lower Objective Reflux Burden
Alimentary Pharmacology & Therapeutics · 2026-08 · 64 (4) · 471-478
DOI: 10.1111/apt.70713 ↗At a glance
Multizentrische Studie in Alimentary Pharmacology & Therapeutics, published online on 2026-05-10. Written by Walter W Chan and 5 co-authors. Institution: Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Major MEDLINE topics: Gastroesophageal Reflux, Asian People. Cited 6 times so far (Crossref); 26 references. The full text is freely available in PubMed Central. Funded by: NIDDK NIH HHS, NIH HHS, National Institutes of Health.
Abstract (original language)
Background
Symptoms and reflux burden in gastroesophageal reflux disease ( GERD ) may vary between populations.
Aims
To evaluate relationships between symptom profiles and objective reflux burden in patients in two world regions, Asia and the United States.
Methods
This was a cross‐sectional study of patients undergoing pH ‐impedance monitoring from one Asian and two US centres. Validated patient‐reported symptom instruments were prospectively collected. Symptom characteristics were compared against objective reflux burden (acid exposure time, AET ; total reflux episodes, TRE ; mean nocturnal baseline impedance, MNBI ) from pH ‐impedance monitoring between the two populations.
Results
Of 1099 patients, 162 were in Asia (age 47.4 ± 1.1 years, 36.4% female, body mass index, BMI 24.2 ± 0.4 kg/m 2 ) and 937 in the United States (53.1 ± 1.3 years, 67.7% female, BMI 30.1 ± 0.3 kg/m 2 ). Regurgitation dominated in Asia (59.9% vs. 50.3% heartburn in the United States), with higher TRE (55.4 ± 2.4 vs. 46.4 ± 1.2, p < 0.001). Despite this, reflux burden was lower in Asia (mean AET 2.19% ± 0.4% vs. 3.53% ± 0.2%; pathologic AET 11.1% vs. 20.5%; MNBI 2472 ± 62 Ω vs. 1745 ± 81 Ω; conclusive GERD per Lyon 2.0: 13% vs. 25.7%) (all p < 0.001), with higher symptom burden (GERDQ 8.97 ± 0.2 vs. 8.44 ± 0.1, p < 0.05; global symptom severity, GSS: 65.1 ± 1.8 vs. 48.1 ± 1.1, p = 0.001). Changing the AET threshold to 4% increased diagnostic yield by 21% among Asians ( p = 0.035 vs. US). On multivariable linear regression, Asian patients (β = 19.3, p < 0.0001), higher AET (β = 1.02, p = 0.0004), higher reflux episodes (β = 0.11, p = 0.0029), lower BMI (β = −0.37, p = 0.0046) and female sex (β = 8.14, p = 0.0007) were independent predictors for higher GSS.
Conclusions
Compared to US patients, GERD profiles in Asian patients associate with higher symptom reporting despite lower objective reflux burden.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Hualien, Taiwan.
- Division of Gastroenterology, Washington University School of Medicine, St. Louis, Missouri, USA.
ORCID profiles: Chien-Lin Chen
Funding
- NIDDK NIH HHS
- NIH HHS
- National Institutes of Health
Cite
APA
Chan, W. W., Wong, M. W., Schroeder, M. K., Richardson, A. G., Chen, C. L., & Gyawali, C. P. (2026). Asian Patients Report Higher Reflux Symptom Burden than US Patients Despite Lower Objective Reflux Burden. Alimentary Pharmacology & Therapeutics, 64(4), 471-478. https://doi.org/10.1111/apt.70713
Vancouver
Chan WW, Wong MW, Schroeder MK, Richardson AG, Chen CL, Gyawali CP. Asian Patients Report Higher Reflux Symptom Burden than US Patients Despite Lower Objective Reflux Burden. Alimentary Pharmacology & Therapeutics. 2026;64(4):471-478. doi:10.1111/apt.70713
BibTeX
@article{Chan2026,
author = {Chan, Walter W and Wong, Ming-Wun and Schroeder, Matthew K and Richardson, Allyson G and Chen, Chien-Lin and Gyawali, C Prakash},
title = {Asian Patients Report Higher Reflux Symptom Burden than US Patients Despite Lower Objective Reflux Burden},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
volume = {64},
number = {4},
pages = {471--478},
doi = {10.1111/apt.70713}
}
EUVIMED